Wednesday, April 17, 2019
AngioDynamics’ DIRECT Clinical Study Receives Institutional Review Board Approval for the Treatment of Stage III Pancreatic Cancer
LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 17, 2019-- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the Company received central Institutional Review Board (IRB)...

  Tuesday, April 2, 2019
AngioDynamics Reports Fiscal 2019 Third Quarter Financial Results
Fiscal 2019 Third Quarter Highlights Net sales of $86.3 million , an increase of 3.0% year over year Gross margin declined 10 basis points year over year to 54.1% GAAP EPS of $0.02 per share; adjusted EPS of $0.19 per share Cash provided by operations of $8.3 million ; capital expenditures of $0.9...

  Monday, April 1, 2019
AngioDynamics to Present at the Needham Healthcare Conference
LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 1, 2019-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Michael C. Greiner , Executive Vice President and Chief...

  Monday, April 1, 2019
AngioDynamics Receives FDA Approval to Initiate NanoKnife® DIRECT Clinical Study for the Treatment of Stage III Pancreatic Cancer
LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 1, 2019-- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that the United States Food and Drug Administration ( FDA ) approved...

  Thursday, March 28, 2019
CORRECTING and REPLACING OARtrac® Radiation Dose Monitoring System Receives Expanded FDA Clearance for Electron Radiation Therapy
LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 28, 2019-- Second paragraph, first sentence of release should read: The additional indications clear the OARtrac System for use with patient-specific, pre-calibrated Plastic Scintillating Detector (PSD) sensors used during cancer treatments to measure photon and...

  Tuesday, March 12, 2019
AngioDynamics to Report Fiscal 2019 Third Quarter Financial Results on April 2, 2019
LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 12, 2019-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the third quarter of...

  Friday, March 8, 2019
AngioDynamics Wins Patent Infringement Dispute With Bard
LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 8, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that the United States District Court for the District of Delaware ,...

  Tuesday, February 26, 2019
AngioDynamics to Present at the Barclays Global Healthcare Conference
LATHAM, N.Y. --(BUSINESS WIRE)--Feb. 26, 2019-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and...

  Friday, January 4, 2019
AngioDynamics Reports Fiscal 2019 Second Quarter Financial Results
Fiscal 2019 Second Quarter Highlights Net sales of $91.5 million , an increase of 5.5% year over year Gross margin expanded 440 basis points year over year to 53.7% GAAP EPS of $0.06 per share; adjusted EPS of $0.22 per share Cash provided by operations of $13.0 million ; capital expenditures of...

  Thursday, December 20, 2018
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 20, 2018-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and...

  Monday, December 10, 2018
AngioDynamics to Report Fiscal 2019 Second Quarter Financial Results on January 4, 2019
LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 10, 2018-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the second quarter of...

  Thursday, September 27, 2018
AngioDynamics Reports Fiscal 2019 First Quarter Financial Results
Fiscal 2019 First Quarter Highlights Net sales of $85.3 million , flat versus prior year Gross margin expanded 380 basis points year over year to 52.1% GAAP EPS of $(0.01) per share; adjusted EPS of $0.16 per share Cash used in operations of $8.9 million ; capital expenditures of $0.7 million...

  Wednesday, September 19, 2018
AngioDynamics to Present at the Cantor Global Healthcare Conference
LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 19, 2018-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Michael C. Greiner , Executive Vice President and Chief...

  Thursday, September 13, 2018
AngioDynamics to Report Fiscal 2019 First Quarter Financial Results on September 27, 2018
LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 13, 2018-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the first quarter of...

  Thursday, September 13, 2018
AngioDynamics to Acquire RadiaDyne and its Revolutionary OARtrac® Radiation Dose Monitoring Platform to Further Expand Oncology Portfolio
LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 13, 2018-- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced an agreement to acquire RadiaDyne, a privately held medical...